Emyria (ASX:EMD) launches MDMA-assisted therapy for PTSD patients

themarketherald.com.au
3 min read
fairly difficult
Emyria (ASX:EMD) has launched a psychedelic-assisted therapy programme targeting treatment-resistant post-traumatic stress disorder.
Be the first with the news that moves the market

Subscribe Be the first with the news that moves the market

Emyria (EMD) has launched a psychedelic-assisted therapy programme targeting treatment-resistant post-traumatic stress disorder

In partnership with Mind Medicine Australia, the EMDMA-001 programme is hoped to help evaluate the long-term safety and efficacy of MDMA-assisted psychotherapy

The phase two clinical trial for MDMA-assisted therapy is set to take place at Emyria's clinic in Melbourne once ethics approval has been granted, although it is unclear when this might take place

Emyria's Managing Director, Dr Michael Winlo, said there is growing international interest in the promise of psychedelic-assisted therapies

Emyria shares are down 3.85 per cent trading at 25…
Simone Grogan
Read full article